3SBio Inc
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more
3SBio Inc (83B) - Total Liabilities
Latest total liabilities as of June 2025: €4.89 Billion EUR
Based on the latest financial reports, 3SBio Inc (83B) has total liabilities worth €4.89 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
3SBio Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how 3SBio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
3SBio Inc Competitors by Total Liabilities
The table below lists competitors of 3SBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HIMS
MX:HIMS
|
Mexico | MX$1.61 Billion |
|
Vicor Corporation
NASDAQ:VICR
|
USA | $79.89 Million |
|
Mercury Systems Inc
NASDAQ:MRCY
|
USA | $1.04 Billion |
|
Travel + Leisure Co
NYSE:TNL
|
USA | $7.71 Billion |
|
Informatica Inc
NYSE:INFA
|
USA | $2.85 Billion |
|
FPT Corp
VN:FPT
|
Vietnam | ₫44.34 Trillion |
Liability Composition Analysis (2016–2024)
This chart breaks down 3SBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 3SBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 3SBio Inc (2016–2024)
The table below shows the annual total liabilities of 3SBio Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €6.18 Billion | -13.15% |
| 2023-12-31 | €7.11 Billion | +7.94% |
| 2022-12-31 | €6.59 Billion | +44.64% |
| 2021-12-31 | €4.55 Billion | -0.66% |
| 2020-12-31 | €4.58 Billion | +3.03% |
| 2019-12-31 | €4.45 Billion | -9.78% |
| 2018-12-31 | €4.93 Billion | -19.45% |
| 2017-12-31 | €6.12 Billion | +43.32% |
| 2016-12-31 | €4.27 Billion | -- |